Innogenetics showcases its LUMIPULSE® G1200 for the first time in Europe at the SIMEL/SIBIOC congress

Product news

Ghent, Belgium: November 16, 2011 - Innogenetics, an international diagnostics company that develops and markets diagnostic products to improve therapy management and patient health, announced the Italian launch of its LUMIPULSE® G1200, a fully automated chemiluminescent enzyme immunoassay (CLEIA) system, at the 1° Congresso della Medicina di Laboratorio (SIMel/SIBioC) in Parma, Italy on November 16.

The LUMIPULSE® series was originally introduced on the Japanese market by Fujirebio, Innogenetics’ mother company. With the series Fujirebio has become market leader in Japan in the domain of immunoassay testing of oncology and infectious diseases markers. Today more than 1.300 units of the LUMIPULSE® series perform tests daily in hospitals and clinical laboratories across Japan. The LUMIPULSE® G1200, a widely improved mid-sized instrument from the series, was launched by Fujirebio in 2008.

Among the many competitive features that have built the success of the LUMIPULSE® G1200 in Japan are the unique mono test cartridge concept and a true throughput of 120 t/h providing outstanding flexibility and easy handling to clinical laboratories. Another important asset of the LUMIPULSE® G1200 is a broad assay menu; the immediately available menu in Italy is expected to grow rapidly and today already includes quality markers such as for oncology, syphilis, thyroid, fertility and diabetes (non exhaustive list).

”With the LUMIPULSE® G1200, Italian and European labs will have access to Fujirebio’s expertise in oncology and infectious diseases and the flexibility of a proven robust platform connectable to full automation solutions and in high safety environments. LUMIPULSE® perfectly fits current and future expectations of European laboratories”, says Philippe Grandjean, Global Marketing Director of Innogenetics.

Fujirebio acquired Centocor Dx (now Fujirebio Diagnostics, Inc., FDI) in 1998, and in 2006 FDI acquired Can Ag Dx. Fujirebio is today recognized as the world-wide market leader in oncology for both routine and novel markers, providing high added value information to clinicians. Fujirebio’s strong presence and reputation in infectiology both in clinical labs and blood banks, in particular screening for syphilis in blood donations, will now allow European labs to have access to a set of unique testing solutions.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.